The shareholders of Acarix AB, reg. no. 559009-0667, (the ”Company”), are hereby convened to the
annual general meeting to be held on Wednesday 23 May 2018, at 10.00 at Baker & McKenzie
Advokatbyrå’s premises at Vasagatan 7 in Stockholm.
Press releases
Aktieägarna i Acarix AB, org.nr 559009-0667, (”Bolaget”) kallas härmed till årsstämma onsdagen
den 23 maj 2018 kl. 10.00 i Baker & McKenzie Advokatbyrås lokaler på Vasagatan 7 i Stockholm.
Acarix was established in 2009, and since 2010 investors Sunstone Life Science Ventures (DK) and
SEED Capital (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First
North Premier in 2016 and has attracted a highly-experienced management team.
Acarix grundades 2009 och sedan 2010 har danska riskkapitalföretagen Sunstone Life Science Ventures
och Seed Capital finansierat utvecklingen av bolaget och stöttat det mot en introduktion på
marknaden. Acarix noterades på Nasdaq First North Premier 2016 och har en mycket erfaren
ledningsgrupp.
CADScor®System launched in key markets: ”In 2017, we achieved historic milestones in Acarix – most noticeably the receipt of our first commercial order for CADScor®System in June and thus a confirmation of the commercialization program being on track.”
CADScor®System lanserat på viktiga marknader: ”Under 2017 uppnådde vi historiska milstolpar på Acarix: den viktigaste var vår första kommersiella order på ett CADScor®System i juni, vilket var en bekräftelse på att kommersialiseringsprogrammet löpte enligt plan. ”
Acarix AB (publ) (“Acarix”) som har utvecklat CADScor®System för riskbedömning av kranskärlssjukdom, tillkännagav idag utnämningen av bolagets nuvarande CFO, Christian Lindholm till interims VD. Lindholm ersätter VD Søren Rysholt Christiansen som meddelade sin avgång den 6 november 2017.
Acarix AB (publ) (“Acarix”), developer of the CADScor®System for Coronary Artery Disease (CAD) risk assessment, today announced the appointment of the company’s current CFO, Christian Lindholm as interim Chief Executive Officer. Lindholm replaces CEO Søren Rysholt Christiansen who announced his resignation on November 6th, 2017.
Handhållet instrument utesluter förekomst av kranskärlsstenos, vilket sparar
värdefull tid som initialt test och leder till att dyr diagnostik kan undvikas.
Handheld system rules out coronary arterial stenosis, saving valuable time in
frontline triage and avoiding the need for expensive diagnostics.
Events
Join us at the Symposium 3, “Ultrasensitive Phonocardiographie” on Friday the 19th of January, from 11.00-12.00
Visit us at booth 51 in room Maritim from October 12 – 14 during the autumn meeting of the German Cardiac Society.
Visit us at booth F140 August 26 – 29 during the Annual Meeting of the European Society of Cardiology in Barcelona.
Visit us at our booth number 47, Room Maritim
Find us in Exhibition 3, at booth # J 690
Reports
In September the registration trial was published in the International Journal for Cardiovascular Imaging.